Evidence map›Paper›PMID 40711160›Full record

Trial reportToxins2025

Efficacy and Safety of Letibotulinum Toxin A for the Treatment of Melasma in Two Different Dilutions: A Randomized Double-Blind Split-Face Study.

Juthapa Pongklaokam, Woraphong Manuskiatti, Rungsima Wanitphakdeedecha, Pitchaya Maneeprasopchoke, Panwadee Thongjaroensirikul, Yanin Nokdhes, Rona Maria R Abad-Constantino, Woramate Bhorntarakcharoen, Sariya Sittiwanaruk, Thanya Techapichetvanich

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Toxins, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Juthapa PongklaokamDepartment of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkok Noi, Bangkok 10700, Thailand.ORCID 0009-0001-1018-6780
Woraphong ManuskiattiDepartment of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkok Noi, Bangkok 10700, Thailand.ORCID 0000-0001-8393-7963
Rungsima WanitphakdeedechaDepartment of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkok Noi, Bangkok 10700, Thailand.ORCID 0000-0002-3926-2193
Pitchaya ManeeprasopchokeDepartment of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkok Noi, Bangkok 10700, Thailand.
Panwadee ThongjaroensirikulDepartment of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkok Noi, Bangkok 10700, Thailand.
Yanin NokdhesDepartment of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkok Noi, Bangkok 10700, Thailand.
Rona Maria R Abad-ConstantinoDepartment of Dermatology, Research Institute for Tropical Medicine, 9002 Research, Mutinlupa 1781, Philippines.
Woramate BhorntarakcharoenDepartment of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkok Noi, Bangkok 10700, Thailand.ORCID 0009-0002-1092-455X
Sariya SittiwanarukDepartment of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkok Noi, Bangkok 10700, Thailand.
Thanya TechapichetvanichDepartment of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkok Noi, Bangkok 10700, Thailand.ORCID 0000-0001-9590-8887

Funding

Hugel Inc., located at 61-20, Sinbuk-ro, Sinbuk-eup, Chuncheon-si, Gangwon-do, 24203, Republic of Korea. IIT-HG-Tx-20250610-01
6 · The paper itself

Abstract

backgroundMelasma is an acquired hyperpigmentation disorder with multifactorial etiologies and limited response to conventional therapies. Recent evidence suggests that Botulinum Toxin A (BoNT-A) may modulate ultraviolet (UV)-induced pigmentation and offer therapeutic benefits.

objectiveWe sought to evaluate the efficacy and safety of two intradermal dilutions of Letibotulinum toxin A (LetiBoNT-A) in Thai patients with melasma.

methodsIn this randomized, double-blind, split-face study, 30 participants aged 32-62 years received a single intradermal injection of LetiBoNT-A, with 20 units administered per cheek. A 1:5 dilution was injected on one side of the face, and a 1:10 dilution was injected on the contralateral side. Outcomes were evaluated over a 6-month period using the Hemi-modified Melasma Area and Severity Index (Hemi-mMASI), VISIA

resultsBoth dilutions significantly improved Hemi-mMASI scores (1:5,

conclusionsLetiBoNT-A is a safe and effective adjunct in melasma treatment. The 1:10 dilution offered superior clinical outcomes.

Indexed as

Botulinum Toxins, Type AMelanosisAdultDouble-Blind MethodFemaleHumansInjections, IntradermalMaleMiddle AgedTreatment OutcomeBotulinum Toxins, Type AhyperpigmentationLetibotulinum toxin Amelasma

Identifiers

PMID40711160
PMCPMC12299615

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.